Peter Ton Dijke

Title: Innovations of Peter Ton Dijke in Cancer Research

Introduction

Peter Ton Dijke is a prominent inventor based in Uppsala, Sweden. He has made significant contributions to the field of cancer research, particularly through his innovative work on the Smad2 protein. His research focuses on the mechanisms of phosphorylation and the interactions of Smad2 with other proteins, which are crucial for understanding cancer pathways.

Latest Patents

Peter Ton Dijke holds a patent related to "Smad2 phosphorylation and interaction with Smad4." This invention describes the amino acid residues of the Smad2 protein that are important for its phosphorylation and activity. It includes Smad2 polypeptide fragments and biologically functional variants, including dominant-negative variants of Smad2 and related antibodies. The patent also covers nucleic acids that encode such variants and methods for utilizing these nucleic acids and polypeptides in research and therapeutic applications.

Career Highlights

Peter Ton Dijke is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer biology. His work has been instrumental in elucidating the role of Smad proteins in cellular signaling pathways, which has implications for cancer treatment and understanding tumor biology.

Collaborations

Peter has collaborated with notable researchers in his field, including Ester Piek and Kiyoshi Tamaki. These collaborations have further enriched his research and contributed to the advancement of knowledge in cancer biology.

Conclusion

Peter Ton Dijke's innovative work and patent contributions significantly enhance our understanding of cancer mechanisms. His research continues to pave the way for potential therapeutic advancements in cancer treatment.